Zobrazeno 1 - 10
of 847
pro vyhledávání: '"Manikhas, A."'
Autor:
Liudmila G. Zhukova, Larisa V. Bolotina, Victoria V. Dvornichenko, Natalia V. Fadeeva, Inna P. Ganshina, Katerina S. Grechukhina, Alfiya I. Hasanova, Nikolay V. Kislov, Igor Yu. Kudryavtsev, Alexey G. Manikhas, Natalia E. Musaeva, Alexandra A. Nizhegorodtseva, Olga E. Sadikova, Dina D. Sakaeva, Anton V. Snegovoy, Daniil L. Stroyakovskiy, Sergei A. Tjulandin, Ekaterina A. Trishkina, Liubov Iu. Vladimirova, Nikita M. Volkov, Yulia V. Kostalanova
Publikováno v:
Современная онкология, Vol 26, Iss 1, Pp 56-64 (2024)
Background. The use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy is a key initial treatment for advanced luminal HER2-negative (HR+/HER2-) breast cancer. The approval studies MONALEESA-2 and 7 demonstra
Externí odkaz:
https://doaj.org/article/38d513dc74f248e7bd74c0e83c57a19a
Autor:
Naveen Reddy, Pramod Reddy, Ankit Ranpura, Narendra Maharaj, Rajendersingh Arora, Gopichand Mamillapalli, Aditya Shirish Adhav, Ashok Kumar Diwan, Alexey Manikhas, Dmitriy Krasnozhon
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSEDr Reddy's Laboratories Trastuzumab (DRL_TZ) is a biosimilar to Herceptin under development. The present study was conducted to evaluate efficacy, safety, pharmacokinetics (PKs), and immunogenicity of DRL_TZ in comparison with the reference me
Externí odkaz:
https://doaj.org/article/bba45b8803a44c0facf72a83a258f0a3
Autor:
Xavier Pivot, Alexey Georgievitch Manikhas, Volodymyr Shamrai, Giorgi Dzagnidze, Hwoei Fen Soo Hoo, Viriya Kaewkangsadan, Fausto Petrelli, Cristian Villanueva, Jamie Kim, Sumita Pradhan, Litha Jaison, Peggy Feyaerts, Leonard Kaufman, Marie-Paule Derde, Filip Deforce, David G. Cox
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background The TROIKA trial established that HD201 and trastuzumab were equivalent in terms of primary endpoints (total pathological complete response) following neoadjuvant treatment. The objective of the present analysis was to compare sur
Externí odkaz:
https://doaj.org/article/6c8d15b8875948eb849c5e19e8288c4d
Publikováno v:
Опухоли женской репродуктивной системы, Vol 18, Iss 2, Pp 14-20 (2022)
Background. Comprehensive treatment of breast cancer includes surgery, radiation therapy and systemic treatment. Radiation therapy plays an integral role in the treatment of early breast cancer. The appointment of a targeted dose of radiation to the
Externí odkaz:
https://doaj.org/article/c4e50f2ef24f4f46b1d8bd74426da182
Autor:
Joseph Gligorov, Xavier Pivot, Beyhan Ataseven, Michelino De Laurentiis, Kyung Hae Jung, Alexey Manikhas, Hamdy Abdel Azim, Kushagra Gupta, Ari Alexandrou, Luis Herraez-Baranda, Nadia Tosti, Eleonora Restuccia
Publikováno v:
Breast, Vol 64, Iss , Pp 151-158 (2022)
Aim: To report the final results of the 5-year follow-up of the non-randomized SafeHER Phase III study (NCT01566721) describing the safety, tolerability, and efficacy of subcutaneous (SC) trastuzumab alone and in combination with concurrent or sequen
Externí odkaz:
https://doaj.org/article/17375d004c944ad6ba82bb82c1a364c7
Publikováno v:
Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова, Vol 28, Iss 4, Pp 48-55 (2022)
Introduction. Elderly and senile patients are a special category of patients and standard methods in breast cancer treatment are not suitable due to the frequent presence of serious comorbidities and personal preferences and concerns about treatment
Externí odkaz:
https://doaj.org/article/17774a4c6274400aa74648925d76a1ea
Autor:
L. A. Tashireva, N. O. Popova, V. V. Alifanov, V. E. Goldberg, E. I. Kovalenko, E. V. Artamonova, A. G. Manikhas, D. M. Ponomarenko, N. V. Levchenko, E. I. Rossokha, S. Yu. Krasilnikova, M. A. Zafirova, V. M. Perelmuter
Publikováno v:
Опухоли женской репродуктивной системы, Vol 17, Iss 4, Pp 48-55 (2022)
Background. Triple negative breast cancer has no specific treatment sites for chemotherapy and is unfavorable in terms of prognosis. One of the drugs widely used in this cohort of patients is eribulin, which in addition to its antimitotic effect has
Externí odkaz:
https://doaj.org/article/04fa079dcbd74e2faf1af1a6011b0a93
Autor:
E. I. Kovalenko, E. V. Artamonova, L. V. Bolotina, L. A. Zhiliaeva, D. M. Ponomarenko, E. V. Karabina, G. Z. Mukhametshina, A. I. Khasanova, E. Yu. Ratner, A. R. Safarova, A. G. Manikhas, N. O. Popova, I. V. Evstigneeva, L. Yu. Vladimirova, L. V. Kramskaya, T. V. Karandeeva, I. R. Suslova, O. V. Romanchuk, V. E. Shikina, A. Yu. Povyshev, M. A. Osipov, E. M. Cherniakova, A. S. Dergunov, M. V. Volkonskiy, I. S. Chernov, I. E. Shumskaya, M. M. Fael, V. I. Garifullina, I. E. Gudkova
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 36-46 (2021)
Introduction. The standard of 1st line treatment of HER2+ metastatic breast cancer (mBC) is double blockade with trastuzumab and pertuzumab + taxane, 2nd line – Trastuzumab-emtazine. There are no standards for further treatment, as well as the opti
Externí odkaz:
https://doaj.org/article/ddfb182fcf6247f0b4a7bd188e53d850
Autor:
Hope S. Rugo, Eduardo J. Pennella, Unmesh Gopalakrishnan, Miguel Hernandez-Bronchud, Jay Herson, Hans Friedrich Koch, Subramanian Loganathan, Sarika Deodhar, Ashwani Marwah, Alexey Manikhas, Igor Bondarenko, Joseph D. Parra, Maria Luisa T. Abesamis-Tiambeng, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Sirshendu Roy, Eduardo Patricio Yanez Ruiz, Abhijit Barve, Cornelius F. Waller
Publikováno v:
Breast, Vol 58, Iss , Pp 18-26 (2021)
Background: Trastuzumab-dkst is a biosimilar of trastuzumab. The phase 3 HERITAGE trial demonstrated equivalent overall response rate (ORR) with trastuzumab-dkst or originator trastuzumab at 24 weeks in patients with HER2-positive metastatic breast c
Externí odkaz:
https://doaj.org/article/398ce9856ea34116bdedd35208f23846
Autor:
Hamilton, Erika, Cortes, Javier, Ozyilkan, Ozgur, Chen, Shin-Cheh, Petrakova, Katarina, Manikhas, Aleksey, Jerusalem, Guy, Hegg, Roberto, Huober, Jens, Chapman, Sonya C., Lu, Yi, Hardebeck, Molly C., Bear, Melissa M., Johnston, Erica L., Martin, Miguel
Publikováno v:
In Clinical Breast Cancer June 2021 21(3):181-190